Link to this page
Physician Data Query
Last uploaded:
August 28, 2024
Jump to:
Preferred Name | tolazamide | |
Synonyms |
4-(p-tolylsulfonyl)-1,1-hexamethylenesemicarbazide Norglycin Tolinase 1-(hexahydro-1H-azepin-1-yl)-3-(p-tolylsulfonyl)urea U-17835 |
|
Definitions |
An intermediate-acting, first-generation sulfonylurea with hypoglycemic activity. Tolazamide is converted into five major metabolites that are excreted into the urine. Tolazamide is more potent than tolbutamide and similar in potency to chlorpropamide on a milligram basis. This agent may cause cholestatic jaundice. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C29502" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C29502" NCI Thesaurus) |
|
ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000775372 |
|
altLabel |
4-(p-tolylsulfonyl)-1,1-hexamethylenesemicarbazide Norglycin Tolinase 1-(hexahydro-1H-azepin-1-yl)-3-(p-tolylsulfonyl)urea U-17835
|
|
cui |
C3282883 C0723773 C0040372 C3282882
|
|
DATE FIRST PUBLISHED |
2015-09-04
|
|
Date last modified |
2015-09-04
|
|
definition |
An intermediate-acting, first-generation sulfonylurea with hypoglycemic activity. Tolazamide is converted into five major metabolites that are excreted into the urine. Tolazamide is more potent than tolbutamide and similar in potency to chlorpropamide on a milligram basis. This agent may cause cholestatic jaundice. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C29502" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C29502" NCI Thesaurus)
|
|
LT |
TRD
|
|
NCI ID |
C29502
|
|
notation |
CDR0000775372
|
|
NSC Code |
70762
|
|
ORIG STY |
Drug/agent
|
|
prefLabel |
tolazamide
|
|
tui |
T109 T121
|
Add comment
Delete | Subject | Author | Type | Created |
---|---|---|---|---|
No notes to display |
Create mapping